Skip to main content

Table 1 Baseline characteristics of the study population

From: Association between baseline glycated hemoglobin level and atrial fibrillation recurrence following cryoballoon ablation among patients with and without diabetes

 

Total

HbA1c ≥ median

HbA1c < median

P value

No.

335

183

152

 

Age, years

61.7 ± 9.87

62.84 ± 8.77

60.33 ± 10.93

0.023

Sex

   

0.808

Male

207 (61.8%)

112 (61.2%)

95 (62.5%)

 

Female

128 (38.2%)

71 (38.8%)

57 (37.5%)

 

BMI

25.33 ± 3.18

25.37 ± 3.03

25.29 ± 3.37

0.818

AF type

   

0.097

Paroxysmal

273 (81.5%)

155 (84.7%)

118 (77.6%)

 

Persistent

62 (18.5%)

28 (15.3%)

34 (22.4%)

 

AF duration, months

26.1 ± 33

27.72 ± 32.95

24.15 ± 33.07

0.325

Smoking

35 (10.4%)

22 (12.0%)

13 (8.6%)

0.301

Alcohol habitus

31 (9.3%)

23 (12.6%)

8 (5.3%)

0.022

HTN

99 (29.6%)

42 (23.0%)

57 (37.5%)

0.004

T2DM

43 (12.8%)

27 (14.8%)

16 (10.5%)

0.249

Insulin

14 (4.2%)

9 (4.9%)

5 (3.3%)

0.587

SGLT2i

6 (1.8%)

3 (1.6%)

3 (2.0%)

0.999

CHF

12 (3.6%)

8 (4.4%)

4 (2.6%)

0.394

Stroke/TIA

33 (9.9%)

26 (14.2%)

7 (4.6%)

0.003

CHA2DS2-VASC

1.78 ± 1.49

1.99 ± 1.56

1.52 ± 1.36

0.004

Dyslipidemia

63 (18.8%)

31 (16.9%)

32 (21.1%)

0.338

BNP, pg/mL

92.98 ± 94.6

93.86 ± 102

91.71 ± 83.22

0.858

FBG, mmol/L

4.61 ± 0.66

4.73 ± 0.82

4.46 ± 0.34

< 0.0001

HbA1c, %

5.41 ± 0.5

5.7 ± 0.52

5.06 ± 0.12

< 0.0001

LDL-C, mmol/L

2.45 ± 0.79

2.43 ± 0.79

2.48 ± 0.79

0.6

HDL-C, mmol/L

1.11 ± 0.23

1.14 ± 0.25

1.08 ± 0.18

0.015

TG, mmol/L

2.26 ± 15.02

2.96 ± 20.31

1.42 ± 0.55

0.352

UA, umol/L

338.79 ± 66.08

341.21 ± 76.79

335.87 ± 50.37

0.446

CREA, umolL

65.16 ± 14.82

66.55 ± 14.38

63.48 ± 15.21

0.059

eGFR, ml/min/1.73m2

105.17 ± 19.86

103 ± 18.63

108.47 ± 21.28

0.039

TSH, mIU/L

2.65 ± 1.62

2.71 ± 1.73

2.58 ± 1.48

0.483

FT3, pmol/L

4.75 ± 0.6

4.75 ± 0.58

4.75 ± 0.63

0.994

FT4, pmol/L

16.93 ± 2.2

16.97 ± 2.21

16.88 ± 2.19

0.707

CRP, mg/L

4.74 ± 8.79

4.96 ± 10.81

4.39 ± 4.15

0.628

Hb, g/L

139.84 ± 15.94

140.09 ± 16.05

139.43 ± 15.85

0.761

LAD, mm

40.92 ± 4.38

41.36 ± 3.77

40.37 ± 4.99

0.042

LVEF, %

58.35 ± 4.11

58.45 ± 3.91

58.18 ± 4.43

0.635

IVSTD, mm

9.24 ± 1.99

9.09 ± 1.19

9.41 ± 2.65

0.142

LVPWTD, mm

8.91 ± 1.03

8.89 ± 0.95

8.93 ± 1.11

0.739

LVDD, mm

49.51 ± 5.46

49.46 ± 6.74

49.57 ± 3.29

0.857

PAP, mmHg

26.32 ± 9.36

25.58 ± 10.13

27.48 ± 7.92

0.138

  1. Data expressed as number, mean standard deviation or median (interquartile range)
  2. * p < 0.05 (significant difference between groups)
  3. BMI, body mass index; AF, atrial fibrillation; HTN, hypertension; T2DM, type 2 diabetes mellitus; CHF, chronic congestive heart failure; TIA, transient ischemic attack; FBG, fasting blood glucose; HbA1c, Glycosylated hemoglobin; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglyceride; UA, uric acid; CREA, creatinine; eGFR, estimated glomerular filtration rate; TSH, thyroid stimulating hormone; FT3, free triiodothyronine; FT4, free thyroxine; CRP, C-­reactive protein; Hb, hemoglobin; LAD, left atrial diameter; LVEF, left ventricular ejection fraction; IVSTD, interventricular septal thickness dimensions; LVPWTD, left ventricular posterior wall dimensions; LVDD, left ventricular diastolic diameter; PAP, pulmonary artery pressure; SGLT2i, sodium glucose cotransporter 2 inhibitor; TIA, transient ischemic attack
Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us